Inhalable Dry Powder of Bedaquiline for Pulmonary Tuberculosis: In Vitro Physicochemical Characterization, Antimicrobial Activity and Safety Studies

Bedaquiline is a newly developed anti-tuberculosis drug, conditionally approved by the United States Food and Drug Administration (USFDA) for treating drug-resistant tuberculosis in adults. Oral delivery of bedaquiline causes severe side effects such as increased hepatic aminotransferase levels and...

Descripción completa

Detalles Bibliográficos
Autores principales: Momin, Mohammad A. M., Rangnekar, Bhamini, Sinha, Shubhra, Cheung, Chen-Yi, Cook, Gregory M., Das, Shyamal C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836091/
https://www.ncbi.nlm.nih.gov/pubmed/31581469
http://dx.doi.org/10.3390/pharmaceutics11100502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836091/
https://www.ncbi.nlm.nih.gov/pubmed/31581469
http://dx.doi.org/10.3390/pharmaceutics11100502

Ejemplares similares